HC Wainwright Has Bullish Outlook for PTGX FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Protagonist Therapeutics to $4.61 from $4.00, maintaining a Buy rating and a $221 price target. Its longer-term estimates also improved, including forecasts for FY2029 and FY2030 EPS of $7.60 and $7.78.
• Protagonist reported quarterly EPS of $3.07, above the $2.50 consensus, and revenue of $274.41 million versus expectations of $238.49 million.
• Analyst sentiment is broadly positive: MarketBeat reports an average Buy rating and a consensus price target of $166.67, with 17 analysts rating the stock Buy or Strong Buy.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Protagonist Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $4.61 per share for the year, up from their previous forecast of $4.00. HC Wainwright has a "Buy" rating and a $221.00 price target on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $4.59 per share. HC Wainwright also issued estimates for Protagonist Therapeutics' Q4 2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at $0.31 EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at $0.67 EPS, FY2029 earnings at $7.60 EPS and FY2030 earnings at $7.78 EPS.

Several other research analysts have also recently commented on the company. Johnson Rice set a $165.00 price target on Protagonist Therapeutics in a research note on Friday, July 17th. Weiss Ratings upgraded Protagonist Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, November 4th. The Goldman Sachs Group upgraded Protagonist Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Wall Street Zen raised Protagonist Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Leerink Partners assumed coverage on Protagonist Therapeutics in a research report on Monday, October 12th. They issued an "outperform" rating and a $190.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $166.67.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $135.90 on Tuesday. Protagonist Therapeutics has a 1 year low of $77.00 and a 1 year high of $160.81. The firm has a market cap of $8.79 billion, a price-to-earnings ratio of 28.79 and a beta of 1.21. The stock's 50-day simple moving average is $141.35 and its 200-day simple moving average is $118.09.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.57. The company had revenue of $274.41 million during the quarter, compared to analysts' expectations of $238.49 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in shares of Protagonist Therapeutics during the second quarter valued at $162,357,000. Johnson & Johnson bought a new position in shares of Protagonist Therapeutics during the second quarter worth about $300,220,852. Hsbc Holdings PLC increased its holdings in shares of Protagonist Therapeutics by 1,260.9% in the 2nd quarter. Hsbc Holdings PLC now owns 25,952 shares of the company's stock worth $3,198,000 after acquiring an additional 24,045 shares during the period. Deutsche Bank AG acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth about $17,387,000. Finally, Stempoint Capital LP lifted its position in Protagonist Therapeutics by 22.1% in the 1st quarter. Stempoint Capital LP now owns 72,577 shares of the company's stock valued at $7,650,000 after purchasing an additional 13,147 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company's stock.

Insider Activity

In other news, CEO Dinesh V. Ph D. Patel sold 7,278 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the transaction, the chief executive officer owned 522,968 shares of the company's stock, valued at approximately $75,359,688.80. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the transaction, the chief financial officer owned 59,003 shares of the company's stock, valued at $8,365,445.34. This trade represents a 49.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 183,629 shares of company stock valued at $26,552,987 in the last three months. Insiders own 5.19% of the company's stock.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: HC Wainwright raised estimates across several periods: FY2026 EPS to $4.61 from $4.00; FY2027 loss per share to $0.98 from $2.80; and FY2028 to profit of $0.67 from a projected loss of $2.45. Longer-term forecasts rose sharply, with FY2029 EPS revised to $7.60 from $0.12 and FY2030 to $7.78 from $1.46. The firm also now expects Q4 2027 EPS of $0.31, versus its prior loss estimate of $0.15.
• Positive Sentiment: HC Wainwright maintains a Buy rating and a $221 price target; a separate report says the target was raised to $221. Article: Protagonist Therapeutics Price Target Raised to $221.00

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company's programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.